Dr. 정철원
Dr. Jung Chul Won
학력
2000.08 충북대학교 의과대학원 박사학위 취득
1997.02 서울대학교 의과대학원 석사학위 취득
1987.02 서울대학교 의과대학 졸업
경력
2016.01 ~현재 삼성서울병원 건강보험자문 실차장
2008.03 ~현재 성균관대학교 의과대학 교수
2017.04 ~ 2019.03 삼성서울병원 암병원 통원치료센터장
2017.04 ~ 2019.03 삼성서울병원 혈액종양내과분과장
2002.03 ~ 2008.02 성균관대학교 의과대학 부교수
2004.03 ~ 2005.02 미국 Fred Hutchinson Cancer Research Center, Post-Doc Fellow
2001.03 ~ 2002.02 삼성서울병원 초빙 전문의
1997.09 ~ 2001.02 중앙대학교 의과대학 조교수
1996.03 ~ 1997.08 중앙대학교병원 필동병원 임상강사
1995.03 ~ 1996.02 서울대학병원 전임의 과정 수료
1991.05 ~ 1995.02 서울대학병원 레지던트과정 수료
1987.03 ~ 1988.02 서울대학병원 인턴과정 수료
학회
한국혈전지혈학회 정회원
미국혈액학회 정회원
대한 혈액학회 보험이사
대한 조혈모세포이식학회 평의원
논문
MOL BIOL REP 2019 10.1007/s11033-019-05019-8
Anti-leukemic effects of simvastatin on NRAS(G12D) mutant acute myeloid leukemia cells
Jang1, J; Lee, J; Jang, JH; Jung, CW; Park, S
INT J HEMATOL 2019 10.1007/s12185-019-02749-0
Inotuzumab ozogamicin versus standard of care in Asian patients with relapsed/refractory acute lymphoblastic leukemia
Fujishima1, N; Uchida, T; Onishi, Y; Jung, CW; Goh, YT; Ando, K; Wang, MC; Ono, C; Matsumizu, M; Paccagnella, ML; Sleight, B; Vandendries, E; Fujii, Y; Hino, M
Lancet Haematol 2019 10.1016/S2352-3026(19)30153-X
Romiplostim in patients with refractory aplastic anaemia previously treated with immunosuppressive therapy: a dose-finding and long-term treatment phase 2 trial
Lee1, JW; Lee, SE; Jung, CW; Park, S; Keta, H; Park, SK; Kim, JA; Oh, IH; Jang, JH
GENE CHROMOSOME CANC 2019 10.1002/gcc.22825
Molecular characteristics of terminal deoxynucleotidyl transferase negative precursor B-cell phenotype Burkitt leukemia with IGH-MYC rearrangement
Yoon1, J; Yun, JW; Jung, CW; Ju, HY; Koo, HH; Kim, SH; Kim, HJ
J CLIN LAB ANAL 2019 10.1002/jcla.23064
Next-generation sequencing reveals unique combination of mutations in cis of CSF3R in atypical chronic myeloid leukemia
Yun1, JW; Yoon, J; Jung, CW; Lee, KO; Kim, JW; Kim, SH; Kim, HJ
J CLIN LAB ANAL 2019 10.1002/jcla.22951
Clonal dominance of a donor-derived del(20q) clone after allogeneic hematopoietic stem cell transplantation in an acute myeloid leukemia patient with del(20q)
Yoon1, J; Yun, JW; Jung, CW; Kim, HJ; Kim, SH
BONE MARROW TRANSPL 2019 10.1038/s41409-019-0492-6
Validation of treatment outcomes according to revised severity criteria from European Society for Blood and Marrow Transplantation (EBMT) for sinusoidal obstruction syndrome/veno-occlusive disease (SOS/VOD)
Yoon1, JH; Yoo, KH; Sung, KW; Jung, CW; Kim, JS; Hahn, SM; Kang, HJ; Lee, JH; Im, HJ; Ahn, JS; Kook, H; Cho, B; Lee, JW
LEUKEMIA 2019 10.1038/s41375-018-0321-8
HMGCLL1 is a predictive biomarker for deep molecular response to imatinib therapy in chronic myeloid leukemia
Park1, JH; Woo, YM; Youm, EM; Hamad, N; Won, HH; Naka, K; Park, EJ; Park, JH; Kim, HJ; Kim, SH; Kim, HJ; Ahn, JS; Sohn, SK; Moon, JH; Jung, CW; Park, S; Lipton, JH; Kimura, S; Kim, JW; Kim, D
HAEMATOL-HEMATOL J 2019 10.3324/haematol.2019.218487
Hereditary platelet function disorder from RASGRP2 gene mutations encoding CalDAG-GEFI identified by whole-exome sequencing in a Korean woman with severe bleeding
Yun1, JW; Lee, KO; Jung, CW; Oh, SY; Kim, SH; Choi, CW; Kim, HJ
ANN HEMATOL 2019 10.1007/s00277-019-03624-y
Different prognostic effects of core-binding factor positive AML with Korean AML registry data
Shin1, HJ; Min, WS; Min, YH; Cheong, JW; Lee, JH; Kim, IH; Hong, DS; Ahn, JS; Kim, HJ; Lee, WS; Jung, CW; Jang, JH; Park, Y; Kim, HJ
J CLIN MICROBIOL 2018 10.1128/JCM.00438-18
Comparative Evaluation of QuantiFERON-TB Gold In-Tube and QuantiFERON-TB Gold Plus in Diagnosis of Latent Tuberculosis Infection in Immunocompromised Patients
Ryu1, MR; Park, MS; Cho, EH; Jung, CW; Kim, K; Kim, SJ; Oh, HY; Huh, W; Jang, HR; Koh, WJ; Park, HY; Kim, YH; Sinn, DH; Choi, JO; Joh, JW; Kim, JM; Kim, SJ; Park, JB; Kang, ES
ANN LAB MED 2018 10.3343/alm.2018.38.6.495
Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia
Kim1, HY; Lee, KO; Park, S; Jang, JH; Jung, CW; Kim, SH; Kim, HJ
BONE MARROW TRANSPL 2018 10.1038/s41409-018-0097-5
Satisfaction with sexual activity and sexual dysfunction in hematopoietic stem cell transplantation survivors and their partners: a couple study
Yoo1, KH; Kang, D; Kim, IR; Choi, EK; Kim, JS; Yoon, SS; Lee, CH; Park, S; Kim, SJ; Kim, K; Kim, WS; Jung, CW; Choi, HJ; Jang, JH; Cho, J
ANN HEMATOL 2018 10.1007/s00277-018-3260-6
Genome-wide genotype-based risk model for survival in core binding factor acute myeloid leukemia patients
Park1, S; Choi, H; Kim, HJ; Ahn, JS; Kim, HJ; Kim, SH; Mun, YC; Jung, CW; Kim, D
Cancer Med 2018 10.1002/cam4.1450
A phase 4 study of nilotinib in Korean patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTKorea
Shin1, J; Koh, Y; Yoon, SH; Cho, JY; Kim, DY; Lee, KH; Kim, HJ; Ahn, JS; Kim, YK; Park, J; Sohn, SK; Moon, JH; Lee, YJ; Yoon, S; Lee, JO; Cheong, JW; Ha Kim, K; Kim, SH; Kim, HG; Kim, H; Nam, SH; Do, YR; Park, SG; Park, SK; Bae, SH; Song, HH; Shin, DY; Oh, D; Kim, MK; Jung, CW; Park, S; Kim, I
ONCOTARGET 2018 10.18632/oncotarget.23575
Assessment of a new genomic classification system in acute myeloid leukemia with a normal karyotype
Ahn1, JS; Kim, HJ; Kim, YK; Lee, SS; Ahn, SY; Jung, SH; Yang, DH; Lee, JJ; Park, HJ; Lee, JY; Choi, SH; Jung, CW; Jang, JH; Kim, HJ; Moon, JH; Sohn, SK; Lee, YJ; Won, JH; Kim, SH; Zhang, ZL; Kim, T; Kim, DDH
CLIN CANCER RES 2017 10.1158/1078-0432.CCR-17-0957
Phase III Clinical Trial (RERISE study) Results of Efficacy and Safety of Radotinib Compared with Imatinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia
Kwak1, JY; Kim, SH; Oh, SJ; Zang, DY; Kim, H; Kim, JA; Do, YR; Kim, HJ; Park, JS; Choi, CW; Lee, WS; Mun, YC; Kong, JH; Chung, JS; Shin, HJ; Kim, DY; Park, J; Jung, CW; Bunworasate, U; Comia, NS; Jootar, S; Reksodiputro, AH; Caguioa, PB; Lee, SE; Kim, DW
KOREAN JOURNAL OF INTERNAL MEDICINE 2017 10.3904/kjim.2015.406
Clinical features and treatment outcomes of blastic plasmacytoid dendritic cell neoplasm: a single-center experience in Korea
Kim1, HS; Kim, HJ; Kim, SH; Choi, JY; Ko, YH; Kim, WS; Jung, CW; Kim, SJ
Nutrition. 2017 Apr;36:67-71. doi: 10.1016/j.nut.2016.06.009. Epub 2016 Jun 25.
Patient-Generated Subjective Global Assessment as a prognosis tool in patients with multiple myeloma
Kim HS11, Lee JY2, Lim SH2, Cho J3, Kim SJ2, Jang JH2, Kim WS2, Jung CW2, Kim K4.
Oncotarget. 2017 Jan 31;8(5):8305-8314. doi: 10.18632/oncotarget.14171.
5-Hydroxymethylcytosine correlates with epigenetic regulatory mutations, but may not have prognostic value in predicting survival in normal karyotype acute myeloid leukemia
Ahn JS11,2, Kim HJ1,2, Kim YK1,2, Lee SS1, Ahn SY1, Jung SH1, Yang DH1, Lee JJ1, Park HJ2, Choi SH2, Jung CW3, Jang JH3, Kim HJ4, Moon JH5, Sohn SK5, Won JH6, Kim SH7, Michael S8, Minden MD9, Kim DD9.
J Clin Lab Anal. 2016 Nov;30(6):1061-1070. doi: 10.1002/jcla.21981. Epub 2016 May 2.
Genetic Characteristics of Polycythemia Vera and Essential Thrombocythemia in Korean Patients
Yoo EH11, Park KJ2,3, Won HH2,3, Park JH2,3, Park JH2,3, Lee ST4, Kim HJ4, Bang SM5, Chi HS6, Jung CW7, Kim SH4, Yun H8, Sun CH8, Park I8, Lee S8, Lee C9, Merriman B9, Luo R10, Tan EH10, Park KJ11, Yoo NK11, Kang JJ9, Kim JW12.
J Infect. 2016 Nov;73(5):496-505. doi: 10.1016/j.jinf.2016.06.011. Epub 2016 Jul 7.
Randomized trial of micafungin versus fluconazole as prophylaxis against invasive fungal infections in hematopoietic stem cell transplant recipients
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Chung DR2, Kang CI2, Peck KR2, Jung CW3.
Oncotarget. 2016 Sep 13;7(37):59892-59901. doi: 10.18632/oncotarget.10988.
Blood concentration of cyclosporine during early post-transplant period may have influence on the occurrence of chronic graft versus host disease in patients who received allogeneic hematopoietic stem cell transplantation
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Jung CW1.
Oncotarget. 2016 Aug 23;7(34):54825-54837. doi: 10.18632/oncotarget.10240.
Mutation profiling of 19 candidate genes in acute myeloid leukemia suggests significance of DNMT3A mutations
Shin SY11, Lee ST2, Kim HJ3, Cho EH4, Kim JW3, Park S5, Jung CW5, Kim SH3.
Ann Hematol. 2016 Aug;95(8):1223-32. doi: 10.1007/s00277-016-2691-1. Epub 2016 May 26.
Cytogenetic profiles of 2806 patients with acute myeloid leukemia-a retrospective multicenter nationwide study
Byun JM11, Kim YJ2, Yoon HJ3, Kim SY3, Kim HJ4, Yoon J4, Min YH5, Cheong JW5, Park J6, Lee JH6, Hong DS7, Park SK7, Kim HJ8, Ahn JS8, Shin HJ9, Chung JS9, Lee WS10, Lee SM10, Park Y11, Kim BS11, Lee JH12, Lee KH12, Jung CW13, Jang JH13, Min WS14, Park TS15; AML/MDS working party of Korean Society of Hematology.
J Clin Pathol. 2016 Aug;69(8):737-41. doi: 10.1136/jclinpath-2016-203649. Epub 2016 May 19.
High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: novel mutations and clinical significance
Park CH11, Lee KO2, Jang JH3, Jung CW3, Kim JW1, Kim SH1, Kim HJ1.
J Transl Med. 2016 Mar 24;14:82. doi: 10.1186/s12967-016-0837-5.
Single nucleotide polymorphisms in apoptosis pathway are associated with response to imatinib therapy in chronic myeloid leukemia
Zheng Q11,2, Cao J3, Hamad N4,5, Kim HJ6, Moon JH7, Sohn SK7, Jung CW8, Lipton JH4,5, Kim DD4,5.
Ann Hematol. 2016 Mar;95(4):625-35. doi: 10.1007/s00277-015-2580-z. Epub 2015 Dec 22.
Transplant outcomes of the triple-negative NPM1/FLT3-ITD/CEBPA mutation subgroup are equivalent to those of the favourable ELN risk group, but significantly better than the intermediate-I risk group after allogeneic transplant in normal-karyotype AML
Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
Ann Hematol. 2016 Jan;95(2):301-10. doi: 10.1007/s00277-015-2540-7. Epub 2015 Nov 4.
Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant
Ahn JS11, Kim JY1, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim DD4.
Biol Blood Marrow Transplant. 2016 Jan;22(1):61-70. doi: 10.1016/j.bbmt.2015.07.030. Epub 2015 Jul 31.
DNMT3A R882 Mutation with FLT3-ITD Positivity Is an Extremely Poor Prognostic Factor in Patients with Normal-Karyotype Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation
Ahn JS11, Kim HJ2, Kim YK1, Lee SS1, Jung SH1, Yang DH1, Lee JJ1, Kim NY3, Choi SH3, Jung CW4, Jang JH4, Kim HJ5, Moon JH6, Sohn SK6, Won JH7, Kim SH8, Kim DD9.
Ann Hematol. 2016 Jan;95(2):325-35. doi: 10.1007/s00277-015-2523-8. Epub 2015 Oct 10.
Clinical significance of bone marrow hemophagocytosis in adult patients with malignancy and non-malignancy-induced hemophagocytic lymphohistiocytosis
Lim SH11, Park S1, Jang JH1, Kim K1, Kim HJ2, Kim SH2, Kang CI3, Chung DR3, Peck KR3, Lee J4, Cha HS4, Koh EM4, Ko YH5, Kim WS1, Jung CW1, Kim SJ6,7.
Oncotarget. 2015 Dec 15;6(40):42803-12. doi: 10.18632/oncotarget.5658.
Iron deficient erythropoiesis might play key role in development of anemia in cancer patients
Park S11, Jung CW1, Kim K1, Kim SJ1, Kim WS1, Jang JH1.
Liver Int. 2015 Nov;35(11):2363-9. doi: 10.1111/liv.12838. Epub 2015 Apr 12.
Hepatitis B reactivation in multiple myeloma patients with resolved hepatitis B undergoing chemotherapy
Lee JY11, Lim SH1, Lee MY1, Kim H1, Sinn DH1, Gwak GY1, Choi MS1, Lee JH1, Jung CW1, Jang JH1, Kim WS1, Kim SJ1, Kim K1.
Korean J Intern Med. 2015 Nov;30(6):771-88. doi: 10.3904/kjim.2015.30.6.771. Epub 2015 Oct 30.
Guidelines for the management of myeloproliferative neoplasms
Choi CW11, Bang SM2, Jang S3, Jung CW4, Kim HJ5, Kim HY6, Kim SJ7, Kim YK8, Park J9, Won JH10.
Am J Hematol. 2015 Nov;90(11):1013-20. doi: 10.1002/ajh.24137. Epub 2015 Oct 12.
Long-term follow-up of imatinib plus combination chemotherapy in patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia
Lim SN11, Joo YD1, Lee KH2, Kim DY2, Lee JH2, Lee JH2, Chi HS3, Yun SC4, Lee WS5, Lee SM5, Park S6, Kim I6, Sohn SK7, Moon JH7, Ryoo HM8, Bae SH8, Hyun MS9, Kim MK9, Kim HJ10, Yang DH10, Eom HS11, Lee GW12, Jung CW13, Won JH14, Kim H15, Lee JH16, Shin HJ17, Jang DY18.
Transpl Infect Dis. 2015 Oct;17(5):679-87. doi: 10.1111/tid.12424. Epub 2015 Sep 26.
Incidence of infection according to intravenous immunoglobulin use in autologous hematopoietic stem cell transplant recipients with multiple myeloma
Park S11, Jung CW1, Jang JH1, Kim SJ1, Kim WS1, Kim K1.
Blood Cancer J. 2015 Oct 16;5:e358. doi: 10.1038/bcj.2015.84.
Single monosomy as a relatively better survival factor in acute myeloid leukemia patients with monosomal karyotype
Jang JE11, Min YH1, Yoon J2, Kim I3, Lee JH4, Jung CW5, Shin HJ6, Lee WS7, Lee JH8, Hong DS9, Kim HJ10, Kim HJ2, Park S3, Lee KH4, Jang JH5, Chung JS6, Lee SM7, Park J8, Park SK9, Ahn JS10, Min WS2, Cheong JW1; Korean Society of Hematology AML/MDS Working Party.
Haematologica. 2015 Sep;100(9):e351-3. doi: 10.3324/haematol.2015.126227. Epub 2015 Jun 4.
Adverse prognostic effect of homozygous TET2 mutation on the relapse risk of acute myeloid leukemia in patients of normal karyotype
Ahn JS11, Kim HJ2, Kim YK1, Jung SH1, Yang DH1, Lee JJ1, Lee IK3, Kim NY3, Minden MD4, Jung CW5, Jang JH5, Kim HJ6, Moon JH7, Sohn SK7, Won JH8, Kim SH9, Kim N10, Yoshida K11, Ogawa S11, Kim DD4.
Hum Immunol. 2015 Sep;76(9):636-43. doi: 10.1016/j.humimm.2015.09.009. Epub 2015 Sep 25.
KIR alloreactivity based on the receptor-ligand model is associated with improved clinical outcomes of allogeneic hematopoietic stem cell transplantation: Result of single center prospective study
Park S11, Kim K1, Jang JH1, Kim SJ1, Kim WS1, Kang ES2, Jung CW3.
Blood. 2015 Aug 6;126(6):746-56. doi: 10.1182/blood-2015-03-636548. Epub 2015 Jun 11.
Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia
Kim DY1, Joo YD, Lim SN, Kim SD, Lee JH, Lee JH, Kim DH, Kim K, Jung CW, Kim I, Yoon SS, Park S, Ahn JS, Yang DH, Lee JJ, Lee HS, Kim YS, Mun YC, Kim H, Park JH, Moon JH, Sohn SK, Lee SM, Lee WS, Kim KH, Won JH, Hyun MS, Park J, Lee JH, Shin HJ, Chung JS, Lee H, Eom HS, Lee GW, Cho YU, Jang S, Park CJ, Chi HS, Lee KH; Adult Acute Lymphoblastic Leukemia Working Party of the Korean Society of Hematology.
Leuk Lymphoma. 2015 Jul;56(7):2067-74. doi: 10.3109/10428194.2014.969260. Epub 2014 Nov 20.
Efficacy and safety of ruxolitinib in Asian patients with myelofibrosis
Jung CW11, Shih LY, Xiao Z, Jie J, Hou HA, Du X, Wang MC, Park S, Eom KS, Oritani K, Okamoto S, Tauchi T, Kim JS, Zhou D, Saito S, Li J, Handa H, Jianyong L, Ohishi K, Hou M, Depei W, Takenaka K, Liu T, Hu Y, Amagasaki T, Ito K, Gopalakrishna P, Akashi K.
Eur J Clin Microbiol Infect Dis. 2015 Jul;34(7):1437-41. doi: 10.1007/s10096-015-2370-5. Epub 2015 Apr 17.
Generic piperacillin/tazobactam is not associated with galactomannan false-positivity in adult patients with cancer: a case-control study
Ko JH11, Peck KR, Lee WJ, Lee JY, Cho SY, Ha YE, Kang CI, Chung DR, Jung CW, Kang ES, Song JH.
Oncotarget. 2015 Jun 30;6(18):16653-62.
Platelet response during the second cycle of decitabine treatment predicts response and survival for myelodysplastic syndrome patients
Jung HA11,2, Maeng CH3, Kim M1, Kim S1, Jung CW1, Jang JH1.
Acta Haematol. 2015;134(1):40-8. doi: 10.1159/000368711. Epub 2015 Jun 6.
Azacitidine Pre-Treatment Followed by Reduced-Intensity Stem Cell Transplantation in Patients with Higher-Risk Myelodysplastic Syndrome
Ahn JS11, Kim YK, Min YH, Cheong JW, Jang JH, Jung CW, Kim IH, Yoon HJ, Lee HG, Sohn SK, Moon JH, Kim H, Kim YJ, Won JH, Chung JS, Mun YC, Lee JH, Kim HJ.
Leuk Lymphoma. 2015 May;56(5):1550-1. doi: 10.3109/10428194.2014.971408. Epub 2014 Nov 3.
A case of CD5-positive mature B-cell neoplasm with t(10;14)(q24;q11.2) and trisomy 12
Shin SY11, Lee ST, Kim HJ, Jang JH, Jung CW, Kim SH.
Anticancer Res. 2015 May;35(5):3081-9.
Mutations in the Spliceosomal Machinery Genes SRSF2, U2AF1, and ZRSR2 and Response to Decitabine in Myelodysplastic Syndrome
Hong JY11, Seo JY2, Kim SH3, Jung HA4, Park S4, Kim K4, Jung CW4, Kim JS5, Park JS6, Kim HJ7, Jang JH8.
Ann Lab Med. 2015 Mar;35(2):257-9. doi: 10.3343/alm.2015.35.2.257. Epub 2015 Feb 12.
BRAF V600E and MAP2K1 Mutations in Hairy Cell Leukemia and Splenic Marginal Zone Lymphoma Cases
Shin SY11, Lee ST1, Kim HJ1, Ki CS1, Jung CW2, Kim JW1, Kim SH1.
Platelets. 2015;26(1):38-42. doi: 10.3109/09537104.2013.869312. Epub 2014 Jan 16.
Rebalanced hemostasis in patients with idiopathic thrombocytopenic purpura
Kim WH11, Park JB, Jung CW, Kim GS.
Vox Sang. 2014 Nov;107(4):407-15. doi: 10.1111/vox.12183. Epub 2014 Jul 31.
Incidence and risk factors of poor mobilization in adult autologous peripheral blood stem cell transplantation: a single-centre experience
Lee KH11, Jung SK, Kim SJ, Jang JH, Kim K, Kim WS, Jung CW, Kim DW, Kang ES.
Eur J Clin Microbiol Infect Dis. 2014 Oct;33(10):1847-53. doi: 10.1007/s10096-014-2107-x. Epub 2014 May 23.
Risk factors for cytomegalovirus gastrointestinal diseases in adult patients with cancer
Ko JH11, Peck KR, Lee WJ, Huh K, Yoo JR, Kim K, Cho SY, Ha YE, Kang CI, Chung DR, Jung CW, Kim YH, Lee NY, Kim KM, Song JH.
Leuk Lymphoma. 2014 Oct;55(10):2395-7. doi: 10.3109/10428194.2014.880429. Epub 2014 Mar 7.
Spinal cord compression in multiple myeloma: a single center experience
Jung HA11, Cho SH, Kim SJ, Jang JH, Kim WS, Jung CW, Kim K.
Anticancer Res. 2014 Aug;34(8):4299-306.
Renal Insufficiency in Newly-diagnosed Multiple Myeloma: Analysis According to International Myeloma Working Group Consensus Statement
Park S11, Han B2, Kim K3, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
J Thromb Haemost. 2014 Jul;12(7):1035-43. doi: 10.1111/jth.12611. Epub 2014 Jun 27.
Incidence of venous thromboembolism following major surgery in Korea: from the Health Insurance Review and Assessment Service database
Yhim HY11, Jang MJ, Bang SM, Kim KH, Kim YK, Nam SH, Bae SH, Kim SH, Mun YC, Kim I, Jung CW, Oh D.
Leuk Res. 2014 Jul;38(7):730-6. doi: 10.1016/j.leukres.2014.01.002. Epub 2014 Jan 10.
Allogeneic hematopoietic cell transplantation without total body irradiation from unrelated donor in adult patients with idiopathic aplastic anemia: Fludarabine versus cyclophosphamide-ATG
Kim H11, Lee KH2, Kim I3, Sohn SK4, Jung CW5, Joo YD6, Kim SH7, Kim BS8, Choi JH9, Kwak JY10, Kim MK11, Bae SH12, Shin HJ13, Won JH14, Lee WS15, Oh S16, Kim HJ17, Park JH18; Korean Society of Blood and Marrow Transplantation.
Biomed Res Int. 2014;2014:437852. doi: 10.1155/2014/437852. Epub 2014 Jul 10.
Comparison of the Freiburg and Charlson Comorbidity Indices in Predicting Overall Survival in Elderly Patients with Newly Diagnosed Multiple Myeloma
Kim SM11, Kim MJ1, Jung HA1, Kim K1, Kim SJ1, Jang JH1, Kim WS1, Jung CW1.
Ann Hematol. 2014 Jun;93(6):931-5. doi: 10.1007/s00277-014-2006-3. Epub 2014 Jan 31.
Hereditary gene mutations in Korean patients with isolated erythrocytosis
Jang JH11, Seo JY, Jang J, Jung CW, Lee KO, Kim SH, Kim HJ.
Transfusion. 2014 Jun;54(6):1542-51. doi: 10.1111/trf.12507. Epub 2013 Dec 3.
Deferasirox improves hematologic and hepatic function with effective reduction of serum ferritin and liver iron concentration in transfusional iron overload patients with myelodysplastic syndrome or aplastic anemia
Cheong JW11, Kim HJ, Lee KH, Yoon SS, Lee JH, Park HS, Kim HY, Shim H, Seong CM, Kim CS, Chung J, Hyun MS, Jo DY, Jung CW, Sohn SK, Yoon HJ, Kim BS, Joo YD, Park CY, Min YH; Korean Society of Hematology Acute Myeloid Leukemia/Myelodysplastic Syndrome Working Party.
Acta Haematol. 2014;131(4):193-9. doi: 10.1159/000354839. Epub 2013 Nov 26.
Positive Correlation between Baseline PET or PET/CT Findings and Clinical Parameters in Multiple Myeloma Patients
Park S11, Lee SJ, Chang WJ, Maeng CH, Hong JY, Choi MK, Kim YS, Jung CW, Jang JH, Kim SJ, Kim WS, Choi JY, Kim K.
Int J Hematol. 2014;99(5):635-43. doi: 10.1007/s12185-014-1549-3. Epub 2014 Mar 20.
Multicenter study evaluating the impact of hypomethylating agents as bridging therapy to hematopoietic stem cell transplantation in myelodysplastic syndromes
Kim Y11, Kim IH, Kim HJ, Park S, Lee KH, Kim SJ, Lee JH, Kim DY, Yoon SS, Kim YK, Jang JH, Park SY, Ahn JS, Cheong CW, Lee JH, Cheong JW; Korean Society of Hematology Acute myeloid Leukemia/Myelodysplastic Syndrome Working Party.
Ann Hematol. 2014 May;93(5):877-8. doi: 10.1007/s00277-013-1903-1. Epub 2013 Sep 17.
A unique case of dendritic cell neoplasm from monocyte-derived myeloid origin with distinct immunophenotype and cytomorphology
Jang MA11, Lee ST, Jung CW, Kim SH.
Ann Hematol. 2014 Apr;93(4):603-8. doi: 10.1007/s00277-013-1915-x. Epub 2013 Oct 19.
Clinical significance of SF3B1 mutations in Korean patients with myelodysplastic syndromes and myelodysplasia/myeloproliferative neoplasms with ring sideroblasts
Seo JY11, Lee KO, Kim SH, Kim K, Jung CW, Jang JH, Kim HJ.
Haematologica. 2014 Mar;99(3):561-9. doi: 10.3324/haematol.2013.092023. Epub 2013 Oct 25.
Distinct frequencies and mutation spectrums of genetic thrombophilia in Korea in comparison with other Asian countries both in patients with thromboembolism and in the general population
Kim HJ11, Seo JY, Lee KO, Bang SH, Lee ST, Ki CS, Kim JW, Jung CW, Kim DK, Kim SH.
Anticancer Res. 2014 Feb;34(2):1037-45.
Prognostic Factor Analysis in Core-Binding Factor-positive Acute Myeloid Leukemia
Jung HA11, Maeng CH, Park S, Kim SJ, Kim K, Jang JH, Jung CW.
J Korean Med Sci. 2014 Feb;29(2):164-71. doi: 10.3346/jkms.2014.29.2.164. Epub 2014 Jan 28.
Prevention of Venous Thromboembolism, 2nd Edition: Korean Society of Thrombosis and Hemostasis Evidence-Based Clinical Practice Guidelines
Bang SM11, Jang MJ2, Kim KH3, Yhim HY4, Kim YK5, Nam SH6, Hwang HG7, Bae SH8, Kim SH9, Mun YC10, Kim YK3, Kim I11, Choi WI12, Jung CW13, Park NH14, Choi NK14, Park BJ15, Oh D2, Korean Society of Thrombosis and Hemostasis.
Ann Hematol. 2014 Jan;93(1):99-105. doi: 10.1007/s00277-013-1952-5. Epub 2013 Nov 16.
DCEP for relapsed or refractory multiple myeloma after therapy with novel agents
Park S11, Lee SJ, Jung CW, Jang JH, Kim SJ, Kim WS, Kim K.
Acta Haematol. 2014;131(1):18-27. doi: 10.1159/000351060. Epub 2013 Sep 10.
Clinical Features and Treatment Outcomes of Intravascular Large B-Cell Lymphoma: A Single-Center Experience in Korea
Hong JY11, Kim HJ, Ko YH, Choi JY, Jung CW, Kim SJ, Kim WS.
Br J Haematol. 2013 Oct;163(1):62-71. doi: 10.1111/bjh.12492.
Genome-wide genotype-based risk model for survival in acute myeloid leukaemia patients with normal karyotype
Choi H1, Jung C, Sohn SK, Kim S, Kim HJ, Kim YK, Kim T, Zhang Z, Shin ES, Lee JE, Moon JH, Kim SH, Kim KH, Mun YC, Kim H, Park J, Kim J, Kim D.
Leuk Res. 2013 Oct;37(10):1241-7. doi: 10.1016/j.leukres.2013.06.024. Epub 2013 Jul 18.
Hepatic sinusoidal obstruction syndrome after allogeneic hematopoietic stem cell transplantation in adult patients with idiopathic aplastic anemia
Kim H11, Lee KH, Sohn SK, Jung CW, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Kim MK, Bae SH, Shin HJ, Won JH, Oh S, Lee WS, Park JH, Yoon SS.
Ann Hematol. 2013 Aug;92(8):1101-10. doi: 10.1007/s00277-013-1728-y. Epub 2013 Apr 5.
Escalated daunorubicin dosing as an induction treatment for Philadelphia-negative adult acute lymphoblastic leukemia
Lee SM11, Lee WS, Shin HJ, Lee JJ, Sohn SK, Moon JH, Eom HS, Won JH, Lee KH, Lee JH, Kim DY, Yoon SS, Kim I, Jung CW, Kim SJ, Kim H, Lee JH, Ryoo HM, Lee GW, Kim SH, Mun YC, Kim MK, Joo YD; Korean Society of Hematology Adult ALL working party.
Int J Hematol. 2013 Mar;97(3):388-96. doi: 10.1007/s12185-013-1276-1. Epub 2013 Feb 9.
Inclusion of hemoglobin level in prognostic score provides better prognostic stratification in patients with acute promyelocytic leukemia (APL)
Park S11, Lee SJ, Kim K, Jang JH, Kim DH, Lee KH, Lee JH, Lee JH, Kim DY, Jang DY, Kim H, Park JH, Ryoo HM, Bae SH, Kim MK, Hyun MS, Joo YD, Lee WS, Lee SM, Jung CW.
Ann Oncol. 2013 Mar;24(3):756-60. doi: 10.1093/annonc/mds532. Epub 2012 Oct 31.
Influence of enzyme and transporter polymorphisms on trough imatinib concentration and clinical response in chronic myeloid leukemia patients
Seong SJ11, Lim M, Sohn SK, Moon JH, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Park SY, Yoon SS, Kim I, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Lee HW, Yoon YR.
Genes Chromosomes Cancer. 2013 Jan;52(1):44-55. doi: 10.1002/gcc.22005. Epub 2012 Sep 28.
Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category
Huh J11, Jung CW, Kim HJ, Kim YK, Moon JH, Sohn SK, Kim HJ, Min WS, Kim DH.
Ann Hematol. 2013 Jan;92(2):163-71. doi: 10.1007/s00277-012-1580-5. Epub 2012 Sep 28.
KIT D816 mutation associates with adverse outcomes in core binding factor acute myeloid leukemia, especially in the subgroup with RUNX1/RUNX1T1 rearrangement
Kim HJ11, Ahn HK, Jung CW, Moon JH, Park CH, Lee KO, Kim SH, Kim YK, Kim HJ, Sohn SK, Kim SH, Lee WS, Kim KH, Mun YC, Kim H, Park J, Min WS, Kim HJ, Kim DH; L/MDS working party, Korean Society of Hematology.
Biol Blood Marrow Transplant. 2012 Oct;18(10):1500-8. doi: 10.1016/j.bbmt.2012.03.015. Epub 2012 Apr 1.
Allogeneic Hematopoietic Stem Cell Transplant for Adults over 40 Years Old with Acquired Aplastic Anemia
Kim H11, Lee KH, Yoon SS, Sohn SK, Joo YD, Kim SH, Kim BS, Choi JH, Kwak JY, Hyun MS, Bae SH, Shin HJ, Won JH, Oh S, Lee WS, Park JH, Jung CW; Korean Society of Blood and Marrow Transplantation.
Am J Hematol. 2012 Oct;87(10):961-8. doi: 10.1002/ajh.23281. Epub 2012 Aug 7.
A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia
Huh J11, Kim HJ, Jung CW, Kim HJ, Kim SH, Kim YK, Kim HJ, Shin MG, Moon JH, Sohn SK, Kim SH, Lee WS, Won JH, Mun YC, Kim H, Park J, Min WS, Kim DH; AML/MDS working party, Korean Society of Hematology.
Int J Hematol. 2012 Sep;96(3):327-33. doi: 10.1007/s12185-012-1142-6. Epub 2012 Jul 21.
Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia
Kong JH11, Mun YC, Kim S, Choi HS, Kim YK, Kim HJ, Moon JH, Sohn SK, Kim SH, Jung CW, Dennis Kim DH.
Med Oncol. 2012 Jun;29(2):1179-85. doi: 10.1007/s12032-011-9926-8. Epub 2011 Apr 7.
Patient counseling program to improve the compliance to imatinib in chronic myeloid leukemia patients
Moon JH11, Sohn SK, Kim SN, Park SY, Yoon SS, Kim IH, Kim HJ, Kim YK, Min YH, Cheong JW, Kim JS, Jung CW, Kim DH.
Am J Hematol. 2012 Jan;87(1):37-41. doi: 10.1002/ajh.22193. Epub 2011 Nov 25.
Monosomal karyotype in acute myeloid leukemia predicts adverse treatment outcome and associates with high functional multidrug resistance activity
Ahn HK11, Jang JH, Kim K, Kim HJ, Kim SH, Jung CW, Kim DH.
J Clin Oncol. 2011 Dec 10;29(35):4702-8. doi: 10.1200/JCO.2011.35.5719. Epub 2011 Nov 14.
Adverse Prognostic Impact of Abnormal Lesions Detected by Genome-Wide Single Nucleotide Polymorphism Array-Based Karyotyping Analysis in Acute Myeloid Leukemia With Normal Karyotype
Yi JH11, Huh J, Kim HJ, Kim SH, Kim HJ, Kim YK, Sohn SK, Moon JH, Kim SH, Kim KH, Won JH, Mun YC, Kim H, Park J, Jung CW, Kim DH.
Leuk Lymphoma. 2011 Jun;52(6):1024-9. doi: 10.3109/10428194.2011.563885. Epub 2011 Apr 4.
Trough plasma imatinib levels are correlated with optimal cytogenetic responses at 6 months after treatment with standard dose of imatinib in newly diagnosed chronic myeloid leukemia
Sohn SK11, Oh SJ, Kim BS, Ryoo HM, Chung JS, Joo YD, Bang SM, Jung CW, Kim DH, Yoon SS, Kim H, Lee HG, Won JH, Min YH, Cheong JW, Park JS, Eom KS, Hyun MS, Kim MK, Kim H, Park MR, Park J, Kim CS, Kim HJ, Kim YK, Park EK, Zang DY, Jo DY, Moon JH, Park SY.
Am J Hematol. 2011 Apr;86(4):346-50. doi: 10.1002/ajh.21980.
Retrospective multicenter study on the development of peripheral lymphocytosis following second-line dasatinib therapy for chronic myeloid leukemia
Lee SJ11, Jung CW, Kim DY, Lee KH, Sohn SK, Kwak JY, Kim HJ, Kim IH, Park S, Kim DH.
Int J Hematol. 2011 Mar;93(3):383-8. doi: 10.1007/s12185-011-0797-8. Epub 2011 Mar 1.
Retrospective analysis of paranasal sinusitis in patients receiving hematopoietic stem cell transplantation
Won YW11, Yi SY, Jang JH, Kim K, Kim SJ, Kim WS, Jung CW, Kim DH.
Int J Hematol. 2011 Feb;93(2):163-9. doi: 10.1007/s12185-011-0771-5. Epub 2011 Feb 3.
Clinical features of severe acquired ADAMTS13 deficiency in thrombotic thrombocytopenic purpura: the Korean TTP registry experience
Jang MJ11, Chong SY, Kim IH, Kim JH, Jung CW, Kim JY, Park JC, Lee SM, Kim YK, Lee JE, Jang SS, Kim JS, Jo DY, Zang DY, Lee YY, Yhim HY, Oh D.
Diagnostic and therapeutic guideline for myeloproliferative neoplasm
Am J Hematol. 2010 Nov;85(11):856-62. doi: 10.1002/ajh.21850.
Comprehensive evaluation of time-to-response parameter as a predictor of treatment failure following imatinib therapy in chronic phase chronic myeloid leukemia: Which parameter at which time-point does matter
Kim DH11, Sriharsha L, Jung CW, Kamel-Reid S, Radich JP, Lipton JH.
Ann Hematol. 2010 Jul;89(7):725-31. doi: 10.1007/s00277-010-0910-8. Epub 2010 Feb 24.
Phase IV study evaluating efficacy of escalated dose of imatinib in chronic myeloid leukemia patients showing suboptimal response to standard dose imatinib
Koh Y11, Kim I, Yoon SS, Kim BK, Kim DY, Lee JH, Lee KH, Park E, Kim HJ, Sohn SK, Joo YD, Kim SJ, Chung J, Shin HJ, Kim SH, Kim CS, Song HS, Kim MK, Hyun MS, Ahn JS, Jung CW, Park S; Korean Society of Hematology CML working party.
Int J Hematol. 2010 Jun;91(5):886-91. doi: 10.1007/s12185-010-0580-2. Epub 2010 May 8.
A randomized trial of preemptive therapy for prevention of cytomegalovirus disease after allogeneic hematopoietic stem cell transplantation
Kim ST11, Lee MH, Kim SY, Kim SJ, Kim DH, Jang JH, Kim K, Kim WS, Jung CW.
Jpn J Clin Oncol. 2010 Jun;40(6):556-66. doi: 10.1093/jjco/hyq007. Epub 2010 Feb 25.
Re-analysis of the Outcomes of Post-Remission Therapy for Acute Myeloid Leukemia with Core Binding Factor According to Years of Patient Enrolment
Shin HJ11, Kim HJ, Sohn SK, Min YH, Won JH, Kim I, Yoon HJ, Lee JH, Jo DY, Joo YD, Jung CW, Lee KH; Korean Society of Hematology, AML/MDS Working Party, Chung JS, Ahn JS, Kim SJ, Lee JH, Choi SJ, Lee JH, Bae SH, Hong DS, Zang DY, Kim SH, Lee JL, Bang SM.
Ann Oncol. 2010 Jun;21(6):1179-88. doi: 10.1093/annonc/mdp452. Epub 2009 Oct 29.
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
Kim DH11, Xu W, Kamel-Reid S, Liu X, Jung CW, Kim S, Lipton JH.
J Clin Oncol. 2010 Feb 1;28(4):e54-5. doi: 10.1200/JCO.2009.23.7560. Epub 2009 Nov 16.
Gastric Recurrence of Extramedullary Granulocytic Sarcoma After Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia
Choi ER11, Ko YH, Kim SJ, Jang JH, Kim K, Kang WK, Jung CW, Kim DH.
Eur J Haematol. 2010 Feb 1;84(2):154-9. doi: 10.1111/j.1600-0609.2009.01378.x. Epub 2009 Nov 12.
Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia
Chang MH11, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, Kim K, Jung CW.
Leuk Res. 2010 Feb;34(2):166-72. doi: 10.1016/j.leukres.2009.05.009. Epub 2009 Jun 10.
BCL2 gene polymorphism could predict the treatment outcomes in acute myeloid leukemia patients
Moon JH11, Sohn SK, Lee MH, Jang JH, Kim K, Jung CW, Kim DH.
Haematologica. 2009 Jan;94(1):135-9. doi: 10.3324/haematol.13151. Epub 2008 Dec 9.
Natural killer or natural killer/T cell lineage large granular lymphocytosis associated with dasatinib therapy for Philadelphia chromosome positive leukemia
Kim DH11, Kamel-Reid S, Chang H, Sutherland R, Jung CW, Kim HJ, Lee JJ, Lipton JH.
Leuk Lymphoma. 2008 Apr;49(4):700-9. doi: 10.1080/10428190701843247.
Prognostic implications of the immunophenotype in biphenotypic acute leukemia
Lee JH11, Min YH, Chung CW, Kim BK, Yoon HJ, Jo DY, Shin HJ, Bang SM, Won
동병원 동일과 LIST
유방암
월요일오전 월요일오후
수요일오전
수요일오후
목요일오후
위암,대장암,취담도암,희귀부인암
화요일오전
화요일오후
수요일오후
목요일오후
금요일오전
금요일오후
토요일오전
위암,대장암,육종,간담췌암
수요일오전
수요일오후
목요일오후
금요일오후
토요일오전
유방암,원발부위불명암
월요일오전
화요일오전
화요일오후
목요일오전
금요일오후
타병원 동일과 LIST
서울대학교병원
종양,항암화학요법,대장암,간암,유방암
서울아산병원
골수이식,골수구성백혈병,재생불량성빈혈
가톨릭대학교 서울성모병원
림프종,면역세포치료,조혈모세포이식
서울대학교병원
림프종,폐암,두경부암,흑색종,전이암
건국대학교병원
백혈병,빈혈,림프종,골수종,조혈모세세포이식
신촌세브란스 어린이병원
선천성기형,희귀질환,대사질환,유전자검사
중앙대학교병원
위암,대장암,두경부암,식도암,항암치료
|
|